Sparing and Restoring the Gut Microbiota – A Collaborative Approach to Treating and Preventing Recurrent Clostridioides Diarrhea
October 8, 2020
October 8, 2021
Scroll to the Bottom of this Information to Begin this Course
Supported by educational grants from Ferring Pharmaceuticals, Inc. and Merck & Company.
- Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
This activity is intended for hospitalists, ID specialists, internists, physicians, pharmacists, and other clinicians who care for patients at risk of serious infections.
Dr. Sahil Khanna discusses the role of the microbiome, guideline-recommended therapy, emerging microbiota replacement therapies, and current COVID-19 implications. Dr. Khanna will also review the importance of a healthy microbiota and strategies to prevent dysbiosis and restore balance.
Upon completion of this activity, participants should be better able to:
- Discuss team-based approaches to mitigating and minimizing recurrent C. difficile
- Evaluate the role of the gut microbiota in relationship to C. difficile infection and treatment approaches to reduce recurrent infection
- Review guideline recommendations for the management of first and subsequent recurrences of C. difficile infection
Sahil Khanna, MBBS, MS
Associate Professor of Medicine
Gastroenterology and Hepatology
Physician Accreditation Statement
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Sahil Khanna, MBBS, MS
- Sources of Funding for Research: Ferring Pharmaceuticals, Inc., Rebiotix, Inc.
- Consulting Agreements: Facile Therapeutics, Inc., Premier Inc., Probiotech LLC, Shire PLC
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Instructions for Participation and Credit
This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Melissa Stradal at 773-714-0705 x160
Hardware and Software Requirements
- Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
- Compatible with Windows PC and MAC (256 MB of RAM or higher.)
- Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher.
- Adobe Flash Player 12.0 (or higher).
- Adobe Reader to print certificate.
- Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker.
Disclosure of Unlabeled Use
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational approaches to treating C. difficile infection and reducing recurrent episodes
The content for this activity was developed independently of the commercial supporters. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.